Immunotherapy has continued to establish indications expanding across several cancers in recent years and preliminary clinical data suggest that the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) inhibitors are promising approaches for tumor managements 9. This evidence concerns the gene CTLA4 and cancer.